KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Clinical and Experimental Investigations / 2011 / Cilt: 2 - Sayı: 3

Diyabetik ratların sinir işlevlerinin düzelmesinde gecesafası yağı ve alfa lipoik asidin etkinliği

The effectiveness of evening primrose oil and alpha lipoic acid in recovery of nerve function in diabetic rats

Alaa Eldeen Ahmed EL-KOSSİ
Mostafa Mahmoud ABDELLAH
Abeer Mohamed RASHAD
Sherifa Ahmad HAMED
Sayfa
245–253
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: Compared with untreated diabetic rats, EPO and ALPA resulted in reduction of serum levels of glucose (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Diabetic polyneuropathy is a serious complication of diabetes mellitus and the most frequent neuropathy worldwide.
📊
Temel Bulgular & Veri:Evening primrose oil (EPO) is rich in omega-6 essential fatty acid component and gammalinolenic acid.
💡
Sonuç & Katkı:Results: Compared with untreated diabetic rats, EPO and ALPA resulted in reduction of serum levels of glucose (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: Diabetic polyneuropathy is a serious complication of diabetes mellitus and the most frequent neuropathy worldwide. Evening primrose oil (EPO) is rich in omega-6 essential fatty acid component and gammalinolenic acid. Alpha lipoic acid (ALPA) has a protective effect against lipid peroxidation and helps in scavenging free radicals. Data regarding the effect of treatment with EPO on diabetic parameters and neuropathic manifestations are conflicting. This study aimed to determine the therapeutic efficacy of EPO and ALPA in correcting diabetic parameters and functional and structural neuropathic manifestations in streptozotocin (STZ) induced diabetic rats. Materials and methods: In this study, the effects of two week oral treatment with EPO (1.25 g/kg) was compared to that of ALPA (100 mg/kg) and insulin (2 IU/day), utilized singly or in combination. Results: Compared with untreated diabetic rats, EPO and ALPA resulted in reduction of serum levels of glucose (p

Abstract

Amaç: Diyabetik polinöropati diabetin en ciddi bir komplikasyonudur ve dünyada en yaygın olan nöropatidir. Akşamsefası yağı (EPO) omega-6 esansiyel yağ asit ve gamalinoleik asit bakımından zengindir. Alfa lipoik asit (ALPA) lipid peroksidasyonuna karşı koruyucu bir etkiye sahiptir ve serbest oksijen radikallerini temizlemeye yardımcı olur. EPO tedavisinin diyabet parametreleri ve nöropatik belirtileri üzerine etkisi konusundaki veriler çelişkilidir. Bu çalışma EPO ve ALPA’nın, streptozotosinle diyabet geliştirilen ratlarda, diyabetik parametreleri ve fonksiyonel ve yapısal nöropatik belirtileri düzeltmedeki tedavi etkinliğini belirlemeyi amaçlamıştır. Gereç ve yöntem: Bu çalışmada EPO ile iki haftalık oral tedavi (1.25 g/kg) ALPA (100 mg/kg) ve insülin (2 U/gün) ile tek başına ve kombinasyon şeklinde karşılaştırıldı. Bulgular: Tedavi edilmemiş ratlarla karşılaştırıldığında; EPO ve ALPA, serum glukoz (p

🔖

Bu Makaleye Atıf Yap

EL-KOSSİ, A. E. A., ABDELLAH, M. M., RASHAD, A. M., HAMED, S. A. (2022). Diyabetik ratların sinir işlevlerinin düzelmesinde gecesafası yağı ve alfa lipoik asidin etkinliği. Journal of Clinical and Experimental Investigations, Cilt: 2 - Sayı: 3, 245–253. https://ajindex.com/articles/562181

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Kahler W, Kuklinski B, Ruhlmann C. Diabetes mellitus - a free radical-associated disease. Results of adjuvant antioxidant supplementation. Z Gesamte Inn Med 1993,48(5):223- 32
  2. Apfel SC. Nerve regeneration in diabetic neuropathy. Diab Obes Metab 1999;1(1):3-11
  3. Ryan CM, Geckle MO, Orchard TJ. Cognitive efficiency declines over time in adults with type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia 2003;46(7):940-8
  4. Pierson CR, Zhang W, Sima AA. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuro Exper Neuro 2003;62(7):765-79
  5. Fichera LE, Brenner RR. Isolation and characterization of the haemolymph lipoproteins of Triatoma infestans. Comp Biochem Physiol B 1982;72(1):71-5
  6. Greene DA, Lattimer SA. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myoinositol-mediated defect in sodium-potassium ATPase activity. Diabetes 1984;33(8):712-6
  7. Stevens EJ, Carrington AL, Tomlinson DR. Prostacyclin release in experimental diabetes: effects of evening primrose oil. Prostaglandins Leukot Essent Fatty Acids 1993;49(3):699-706
  8. Stevens MJ, Feldman EL, Greene DA. The etiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 1995;12(7):566-79
  9. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes/Metab Res Rev 2001;17(3):189-212
  10. Sakaue Y, Sanada M, Sasaki T, Kashiwagi A, Yasuda H. Amelioration of retarded neurite outgrowth of dorsal root ganglion neurons by overexpression of PKC-δ in diabetic rats. Neuroreport 2003;14(3):431-6
  11. Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Horm Res 2000;53(2):53-67
  12. Mayer JH, Tomlinson DR. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 1983;25(5):433-8
  13. Ziegler D, Mayer P, Rathmann W, Gries FA. One year treatment with the aldose reductase inhibitor, ponalrestat in diabetic neuropathy. Diabetes Res Clin Pract 1991;14(1):63- 74
  14. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nic